JP Morgan upgraded Hamilton Lane from Neutral to Overweight and set a new price target of $85.00
Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/15/2025 | Outperform → Perform | Oppenheimer | |
| 1/21/2025 | $186.00 | Perform → Outperform | Oppenheimer |
| 1/6/2025 | $139.00 | Neutral → Sell | Goldman |
| 9/12/2024 | $156.00 | Equal Weight | Wells Fargo |
| 4/11/2024 | $115.00 | Overweight → Neutral | JP Morgan |
| 1/11/2024 | Outperform → Perform | Oppenheimer | |
| 5/26/2023 | $87.00 | Perform → Outperform | Oppenheimer |
| 3/15/2023 | $85.00 | Neutral → Overweight | JP Morgan |
8-K - Hamilton Lane INC (0001433642) (Filer)
10-K - Hamilton Lane INC (0001433642) (Filer)
8-K - Hamilton Lane INC (0001433642) (Filer)
Oppenheimer downgraded Hamilton Lane from Outperform to Perform
Oppenheimer upgraded Hamilton Lane from Perform to Outperform and set a new price target of $186.00
Goldman downgraded Hamilton Lane from Neutral to Sell and set a new price target of $139.00
4 - Hamilton Lane INC (0001433642) (Issuer)
The Hamilton Lane Asia Private Assets Fund aims to offer private wealth investors a first-of-its-kind opportunity to tap into Asia's $3+ trillion private equity market1Launch is the latest addition to Hamilton Lane's $11 billion2 global Evergreen PlatformHONG KONG, July 1, 2025 /PRNewswire/ -- Leading private markets investment firm Hamilton Lane (NASDAQ:HLNE) today announced the launch of its Asia Private Assets Fund ("HLAPA" or "the Fund")3, a pioneering semi-liquid vehicle that aims to provide private wealth and institutional investors with diversified access to Asia's private markets landscape.
-- Experienced Industry Leader to drive Cosette's Best-in-Class Quality Organization and facilitate Regulatory Approvals -- Cosette Pharmaceuticals, Inc., a U.S.-based, fully integrated, pharmaceutical company, announced today that it has appointed Jeff Neubig as Vice President, Quality and Regulatory Affairs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250630266171/en/Jeff Neubig, VP, Quality & Regulatory Affairs, Cosette Pharmaceuticals In this critical role, Jeff will lead Cosette's best-in-class quality and regulatory affairs organizations, maintaining the company's rigorous quality standards and further establishing Co
SALT LAKE CITY, June 5, 2025 /PRNewswire/ -- Banner Capital Management, LLC ("Banner") is pleased to announce the closing of a portfolio recapitalization into Banner Capital Fund I ("Fund I") and the launch of Banner Capital Fund II ("Fund II"). Fund I Fund I is a multi-asset continuation fund with over $400 million in capital commitments, formed to acquire interests in eight of Banner's pre-fund portfolio companies. Funds managed by Hamilton Lane (NASDAQ:HLNE) acted as lead investor and many of Banner's pre-fund investors retained a meaningful interest in the portfolio compa
CONSHOHOCKEN, Pa., May 29, 2025 /PRNewswire/ -- Leading private markets asset management firm Hamilton Lane Incorporated (NASDAQ:HLNE) today reported its results for the fourth fiscal quarter and full fiscal year ended March 31, 2025. FISCAL YEAR 2025 HIGHLIGHTS Assets under management – Total assets under management of $138 billion grew 11% year-over-year. Fee-earning assets under management increased 10% to $72 billion over the same period.Revenue – Management and advisory fees increased 14% to $513.9 million for fiscal 2025.Carried Interest – Unrealized carried interest balance of $1.3 billion was up 3% year-over-year.Earnings per share – GAAP EPS of $5.41 on $217.4 million of GAAP net i
CONSHOHOCKEN, Pa., May 8, 2025 /PRNewswire/ -- Hamilton Lane Incorporated (NASDAQ:HLNE) is scheduled to release financial results for the fourth fiscal quarter and full fiscal year ended March 31, 2025 before the market opens on Thursday, May 29, 2025. A copy of the earnings release and full detailed presentation will be available on the Hamilton Lane Shareholders website at https://shareholders.hamiltonlane.com/. Hamilton Lane will host a conference call via webcast at 11:00 a.m. ET on May 29 to discuss the results for the fourth fiscal quarter and full fiscal year. For access to the live event via the webcast, visit Hamilton Lane's Shareholder's website by clicking here (https://sharehold
RED BANK, N.J., April 17, 2025 /PRNewswire/ -- PAX Health, a leading behavioral healthcare company backed by HCAP Partners and funds managed by Hamilton Lane (NASDAQ:HLNE), today announced its acquisition of Richardson Psychiatric Associates, a comprehensive outpatient psychiatric practice serving adults, adolescents, children, and families. This strategic acquisition enhances PAX Health's portfolio of mental health services and expands its geographic footprint in Western Pennsylvania, strengthening the company's ability to deliver high-quality psychiatric care across diverse
3 - Hamilton Lane INC (0001433642) (Issuer)
4 - Hamilton Lane INC (0001433642) (Issuer)
4 - Hamilton Lane INC (0001433642) (Issuer)
-- Experienced Industry Leader to drive Cosette's Best-in-Class Quality Organization and facilitate Regulatory Approvals -- Cosette Pharmaceuticals, Inc., a U.S.-based, fully integrated, pharmaceutical company, announced today that it has appointed Jeff Neubig as Vice President, Quality and Regulatory Affairs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250630266171/en/Jeff Neubig, VP, Quality & Regulatory Affairs, Cosette Pharmaceuticals In this critical role, Jeff will lead Cosette's best-in-class quality and regulatory affairs organizations, maintaining the company's rigorous quality standards and further establishing Co
Grenova, Inc., a Virginia-based innovator in sustainable laboratory technologies, today announced two significant milestones for the company: the appointment of Ted Hull to Grenova's board, and the successful completion of a new round of growth equity capital. These developments support Grenova's strategic vision to drive innovation, expand automation capabilities, and deliver transformative solutions to laboratories worldwide. Ted Hull brings over 30 years of experience in the life sciences industry, including as a clinical lab CEO for the last 20+ years. In his role at Grenova, Mr. Hull is set to provide strategic leadership and to play a pivotal role in shaping the company's future. "I
Industry leader with 35+ years of experience in manufacturing operations and global supply chain excellence Cosette Pharmaceuticals, Inc., a leading specialty pharmaceuticals company, today announced the appointment of Vincent (Vin) Colicchio as Senior Vice President of Operations, effective February 3, 2025. In this role, Vin will lead Cosette's manufacturing, global supply chain, and operational strategy, ensuring efficiency, and supply continuity as the company continues its strong trajectory of growth and transformation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250210366017/en/Senior Vice President, Operations (Photo
SC 13G/A - Hamilton Lane INC (0001433642) (Subject)
SC 13G/A - Hamilton Lane INC (0001433642) (Subject)
SC 13G/A - Hamilton Lane INC (0001433642) (Subject)